Article
Armed Cell Therapeutics Acquires Preclinical CAR-T Portfolio From Lakefront
Armed Cell Therapeutics BV has acquired a portfolio of preclinical CAR-T assets from Lakefront Biotherapeutics NV, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. The acquisition includes multi-targeting and armed CAR-T constructs featuring fully human binders and human protein payloads designed to enhance CAR-T cell potency and persistence. Armed Cell's research teams in the United States and Europe are advancing these programs toward clinical development for patients with hig
Goodwin Procter LLP







